We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Delineates Requirements for Lovenox Biosimilars
EMEA Delineates Requirements for Lovenox Biosimilars
May 12, 2009
Companies planning to make biosimilar drugs to compete with Sanofi-Aventis’ blockbuster blood-clot treatment Lovenox can use a European Medicines Agency (EMEA) guideline that takes effect this October.